AIML Subsidiary NeuralCloud Solutions Engages Lonacas Consultants to Lead Regulatory Submission for CardioYield(TM) in Jamaica

Executive Summary

• AI/ML Innovations’ subsidiary NeuralCloud has engaged Lonacas Consultants to lead the Jamaican regulatory submission for its CardioYield™ AI‑enabled ECG diagnostic platform and wearable chest‑strap device.
• The collaboration supports NeuralCloud’s Caribbean expansion strategy and aims to provide low‑cost, Holter‑grade cardiac diagnostics in Jamaica.
• The Board authorized a grant of 1,405,000 stock options at $0.10 per share to directors, employees and consultants, with staggered vesting beginning on the grant date.

Key Details

• Regulatory Initiative: NeuralCloud Solutions Inc. will submit CardioYield™ software plus single‑lead ECG wearable chest strap for registration with Jamaica’s Ministry of Health & Wellness – Standards and Regulation Division.
• Partner: Lonacas Consultants Ltd., a Kingston‑based clinical research and regulatory consultancy, will manage the end‑to‑end submission process.
• Strategic Goal: Establish a locally regulated, scalable diagnostic ecosystem to address the high burden of cardiovascular disease in Jamaica, especially outside urban centres.
• Product Highlights: CardioYield™ uses AI for rapid ECG signal interpretation; the single‑lead chest strap is designed for durability and comfort in tropical climates, offering Holter‑grade accuracy without multi‑lead adhesives.
• Key Stakeholder Introductions: Jamaican‑Canadian investor Wayne Isaacs facilitated introductions to medical, regulatory and academic stakeholders.
• Leadership Quotes:
• Esmat Naikyar (President, NeuralCloud) – emphasized the importance of formalizing the regulatory pathway for affordable cardiac diagnostics.
• Paul Duffy (Executive Chairman & CEO, AIML) – described the initiative as a foundational step in the company’s broader commercialization roadmap.
• Stock Option Grant: Board approved issuance of 1,405,000 options at an exercise price of $0.10 per common share; vesting schedule: 375,000 on grant date (Nov 4 2025), 125,000 in Feb 2026, 250,000 quarterly over one year, remainder tied to performance milestones. Options expire five years from the grant date.

Notable Quotes

• “The introduction of the CardioYield software, along with its companion ECG wearable device, will be an exciting development in the field of cardiology within Jamaica.” – Wayne Isaacs
• “Our collaboration with Lonacas represents an essential step in making important cardiac care more accessible to the Jamaican population.” – Esmat Naikyar, President, NeuralCloud

Materiality Assessment: Non‑Material – Positive (the release announces a strategic regulatory effort and a routine stock option grant; no immediate financial impact or earnings information disclosed).